342 related articles for article (PubMed ID: 15142457)
1. [Relationship between interleukin-10 level in ascites of patients with primary ovarian epithelial carcinoma and immune defect in peritoneal cavity].
Zhou JW; Cheng Q; Xie X; Chen HZ; Ye DF; Lu WG
Ai Zheng; 2004 May; 23(5):573-6. PubMed ID: 15142457
[TBL] [Abstract][Full Text] [Related]
2. Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer.
Mustea A; Pirvulescu C; Könsgen D; Braicu EI; Yuan S; Sun P; Lichtenegger W; Sehouli J
Cytokine; 2008 Apr; 42(1):77-84. PubMed ID: 18329282
[TBL] [Abstract][Full Text] [Related]
3. Expression of IL-10 in patients with ovarian carcinoma.
Mustea A; Könsgen D; Braicu EI; Pirvulescu C; Sun P; Sofroni D; Lichtenegger W; Sehouli J
Anticancer Res; 2006; 26(2C):1715-8. PubMed ID: 16617566
[TBL] [Abstract][Full Text] [Related]
4. [Serum level and expression of vascular epithelial growth factor in ovarian epithelial carcinoma].
Sun LX; Wu Y; Han HQ; Wang QH
Ai Zheng; 2003 Jan; 22(1):58-61. PubMed ID: 12561438
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of immune inhibitory cytokine profiles in epithelial ovarian carcinoma.
Chen LL; Ye F; Lü WG; Yu Y; Chen HZ; Xie X
J Obstet Gynaecol Res; 2009 Apr; 35(2):212-8. PubMed ID: 19335794
[TBL] [Abstract][Full Text] [Related]
6. [Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer].
Cai Z; Li YF; Liu FY; Feng YL; Hou JH; Zhao MQ
Ai Zheng; 2007 Mar; 26(3):312-7. PubMed ID: 17355798
[TBL] [Abstract][Full Text] [Related]
7. [Expressions of Cx43 and Skp2 in epithelial ovarian tumor and their clinical significances].
Hu YQ; Liu YJ
Ai Zheng; 2005 Jan; 24(1):104-9. PubMed ID: 15642212
[TBL] [Abstract][Full Text] [Related]
8. [Correlation of hK6 expression with clinicopathological features and prognosis in epithelial ovarian cancer].
Hu CJ; Zhang F; Chen YJ; Sun XM; Zheng JF
Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):520-3. PubMed ID: 19950700
[TBL] [Abstract][Full Text] [Related]
9. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity.
Giuntoli RL; Webb TJ; Zoso A; Rogers O; Diaz-Montes TP; Bristow RE; Oelke M
Anticancer Res; 2009 Aug; 29(8):2875-84. PubMed ID: 19661290
[TBL] [Abstract][Full Text] [Related]
10. Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer.
Kusuda T; Shigemasa K; Arihiro K; Fujii T; Nagai N; Ohama K
Oncol Rep; 2005 Jun; 13(6):1153-8. PubMed ID: 15870936
[TBL] [Abstract][Full Text] [Related]
11. High concentrations of activin A in the peritoneal fluid of women with epithelial ovarian cancer.
Cobellis L; Reis FM; Luisi S; Danero S; Pirtoli L; Scambia G; Petraglia F
J Soc Gynecol Investig; 2004 May; 11(4):203-6. PubMed ID: 15120692
[TBL] [Abstract][Full Text] [Related]
12. Myeloid and lymphoid dendritic cells in the peritoneal fluid of women with ovarian cancer.
Wertel F; Polak G; Roliński J; Barczyński B; Kotarski J
Adv Med Sci; 2006; 51():174-7. PubMed ID: 17357302
[TBL] [Abstract][Full Text] [Related]
13. Peritoneal fluid lactate dehydrogenase in ovarian cancer.
Schneider D; Halperin R; Langer R; Bukovsky I; Herman A
Gynecol Oncol; 1997 Sep; 66(3):399-404. PubMed ID: 9299252
[TBL] [Abstract][Full Text] [Related]
14. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.
Bamias A; Koutsoukou V; Terpos E; Tsiatas ML; Liakos C; Tsitsilonis O; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Papatheodoridis G; Archimandritis A; Antsaklis A; Dimopoulos MA
Gynecol Oncol; 2008 Feb; 108(2):421-7. PubMed ID: 18036640
[TBL] [Abstract][Full Text] [Related]
15. [Study on the changes of T-lymphocyte subsets in the patients with endometriosis].
Li JX; Dai SZ; Liu H; Cao YM; Liu SQ
Zhonghua Fu Chan Ke Za Zhi; 2005 Jan; 40(1):17-20. PubMed ID: 15774086
[TBL] [Abstract][Full Text] [Related]
16. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
17. Ovarian carcinoma cells and IL-1beta-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions.
Stadlmann S; Amberger A; Pollheimer J; Gastl G; Offner FA; Margreiter R; Zeimet AG
Gynecol Oncol; 2005 Jun; 97(3):784-9. PubMed ID: 15943987
[TBL] [Abstract][Full Text] [Related]
18. [Soluble interleukin-2 receptor level in the sera and ascitic fluids in patients with ovarian cancer].
Pu FR; Cheng SW; Zhu D
Zhonghua Fu Chan Ke Za Zhi; 1994 Aug; 29(8):478-80, 511. PubMed ID: 7835120
[TBL] [Abstract][Full Text] [Related]
19. [Expressions of VEGF/VEGFRs and activation of STATs in ovarian carcinoma].
Chen BY; Ye DF; Xie X; Chen HZ; Lü WG
Zhonghua Zhong Liu Za Zhi; 2005 Jan; 27(1):33-7. PubMed ID: 15771796
[TBL] [Abstract][Full Text] [Related]
20. [The dose-response of cell proliferation and secretion of CA125 II antigen to follicle stimulating hormone in ovarian cancer cell lines].
Zhu M; Wu Q; Ge B
Zhonghua Fu Chan Ke Za Zhi; 1998 Apr; 33(4):225-6. PubMed ID: 10682470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]